SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ouster, Inc. engages in the provision of high resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets. The company was founded by Angus Pacala and Mark Frichtl on June 30, 2015 and is headquartered in San Francisco, CA.

Ouster Inc - Ordinary Shares - Class A

Ousters Rev8 lidar is drawing attention through integrations and planned deployments in Senecas autonomous wildfire drones, John Deeres orchard machines, and drone-mapping and infrastructure systems, reinforcing the communitys physical-AI growth thesis. Traders are split between optimism about customer traction and scaling production and concern over volatility, valuation, dilution, and execution.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Barclays downgrade of Joby, citing cash burn and doubts about manufacturing capacity, is driving the selloff and comparisons with its upgraded rival Archer. Traders disagree over whether the concerns are justified or the downgrade is a shakeout, with some buying the dip and others moving toward Archer.

Enphase Energy, Inc. is a global energy technology company, which engages in the business of designing, developing, manufacturing, and selling home energy solutions that manage energy generation, energy storage, control, and communications on one intelligent platform. It operates through the following geographical segments: the United States, the Netherlands, and Others. The company was founded by Raghuveer R. Belur and Martin Fornage in March 2006 and is headquartered in Fremont, CA.

Enphase Energy Inc

Enphase is under pressure alongside solar peers as traders cite rising Treasury yields and borrowing costs as headwinds for residential solar demand. The debate is split between bearish calls for further declines and dip buyers looking for a rebound, with some also pointing to the IQ SST data-center power opportunity as a longer-term potential catalyst.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax - ADR

Abivaxs pullback is fueling debate over whether buyout hopes have outrun the near-term case for its ulcerative-colitis drug, obefazimod, despite positive Phase 3 data and a planned FDA filing. Bulls see value in the drugs potential and point to Crohns data as a future catalyst, while skeptics say the lack of a deal could leave the shares waiting on clinical and regulatory milestones; some also cite broader biotech weakness.

Bank of America Corp. is a bank and financial holding company, which engages in the provision of banking and nonbank financial services. It operates through the following segments: Consumer Banking, Global Wealth and Investment Management (GWIM), Global Banking, Global Markets, and All Other. The Consumer Banking segment offers credit, banking, and investment products and services to consumers and small businesses. The GWIM segment focuses on solutions to meet clients’ needs through a full set of investment management, brokerage, banking, and retirement products. The Global Banking segment deals with lending-related products and services, integrated working capital management and treasury solutions to clients, and underwriting and advisory services. The Global Markets segment includes sales and trading services, as well as research, to institutional clients across fixed-income, credit, currency, commodity, and equity businesses. The All Other segment consists of asset and liability management activities, equity investments, non-core mortgage loans and servicing activities, the net impact of periodic revisions to the mortgage servicing rights valuation model for both core and non-core MSRs, other liquidating businesses, residual expense allocations and other. The company was founded by Amadeo Peter Giannini in 1904 and is headquartered in Charlotte, NC.

Bank Of America Corp.

Bank of America Corp

Bank of America is drawing attention amid a sharp bank-stock pullback, with traders citing elevated Treasury yields and concern about the upcoming earnings outlook; the CEOs warning of weaker investment-banking fees and roughly flat trading revenue has added to the pressure. Sentiment is split between traders expecting further declines and buyers who see the pullback as an oversold opportunity ahead of results.

Verizon Communications, Inc. is a holding company, which engages in the provision of communications, information, and entertainment products and services. It operates through the following business segments: Consumer and Business. The Consumer segment provides consumer-focused wireless and wire line communications services and products. The Business segment offers wireless and wireline communications services and products, including FWA broadband, data, video and conferencing services, corporate networking solutions, security and managed network services, local and long-distance voice services, and network access to deliver various IoT services and products. The company was founded in 1983 and is headquartered in New York, NY.

Verizon Communications Inc

Verizon Communications Inc.

Verizon shares sold off on concerns that SpaceXs planned acquisition of low-band spectrum could help Starlink Mobile compete with established wireless carriers. Traders are split between viewing the threat as a long-term risk to subscribers and pricing and calling the selloff overdone given the time and infrastructure needed to build a competing network, alongside Verizons cash flows and dividend.

Citigroup, Inc. is a holding company, which engages in the provision of financial products and services. It operates through the following segments: Services, Markets, Banking, Wealth, U.S. Personal Banking (USPB), and All Other. The Services segment includes Treasury and Trade Solutions (TTS) which provides an integrated suite of tailored cash management, trade, and working capital solutions to multinational corporations, financial institutions and public sector organizations, and Securities Services, which offers cross-border support for clients, providing on-the-ground local market expertise, post-trade technologies, customized data solutions, and a wide range of securities services solutions that can be tailored to meet client needs. The Markets segment provides corporate, institutional, and public sector clients around the world with a full range of sales and trading services across equities, foreign exchange, rates, spread products, and commodities. The Banking segment offers Investment Banking and Corporate Lending services. The Wealth segment includes Private Bank, Wealth at Work, and Citigold and provides financial services to a range of client segments through banking, lending, mortgages, investment, custody, and trust product offerings. The USPB segment includes Branded Cards and Retail Services, which have proprietary card portfolios and co-branded card portfolios within Branded Cards, and co-brand and private label relationships within Retail Services. The All Other segment consists of activities not assigned to the reportable operating segments, including certain unallocated costs of global functions, other corporate expenses, and net treasury results. The company was founded in 1812 and is headquartered in New York, NY.

Citigroup Inc

Rising yields and expectations ahead of Q3 earnings are weighing on bank stocks, with traders concerned about weaker lending and credit quality even as higher rates could support net interest income. Citi discussion is split between investors calling the pullback a buying opportunity and those anticipating cautious results or guidance.

Cash Cat

A sharp pullback after a speculative rally is driving discussion, with traders debating whether CASHCAT is a pump-and-dump with weak support or a dip worth buying. Bulls cite its Robinhood-chain presence and claimed launchpad-driven buybacks and burns, while those claims and rumors of exchange or executive support remain unverified.

Trulieve Cannabis Corp. engages in the cultivation, processing, manufacturing, and retail distribution of medical and adult-use cannabis products. It cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. The company was founded by Kim Rivers & Jason Pernell on September 17, 1940 and is headquartered in Tallahassee, FL.

Trulieve Cannabis Corp - Ordinary Shares (Sub Voting)

Trulieve Cannabis Corp 

A DEA administrative law judges pause in the broader cannabis rescheduling proceeding has fueled debate over the delay and weighed on cannabis stocks, including Trulieve. Traders disagree on how exposed TRLV is: some see an industry-wide overreaction because much of Trulieves business is medical, while others remain concerned about uncertainty around Schedule III and related tax relief.

Select Sector SPDR Trust (The) - State Street Financial Select Sector SPDR ETF

Financial Select Sector SPDR Fund

Financials are under pressure amid rising Treasury yields and concerns about the rate environment weighing on banks, with traders debating whether oversold conditions and upcoming bank earnings could prompt a relief bounce or whether the decline will continue.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

GSK Pharma India Shareholders Approve Appointment of CFO Ronojit Biswas via Postal Ballot

GlaxoSmithKline Pharmaceuticals Limited ( ($IN:GLAXO) ) just unveiled an announcement. GlaxoSmithKline Pharmaceuticals Limited has concluded a post...

GSK Pharma Slapped Rs 23.21 Crore Tax Demand, Plans Appeal

Mumbai: GlaxoSmithKline Pharmaceuticals Limited (GSK Pharma ) has received a tax demand of Rs 23.21 crore from the Income Tax Department following a scrutiny assessment for the Assessment Year 2023-24.

GST Blow: Maharashtra Authorities Slap Rs 6.92 Crore Tax Demand on GSK Pharma

New Delhi: GlaxoSmithKline Pharmaceuticals Limited has received a tax demand … portal and was received physically. GlaxoSmithKline Pharmaceuticals Limited stated that the tax demand …

MP GST Dept Slaps Rs 3.79 Crore Tax, Penalty Demand on GSK Pharma

New Delhi: GlaxoSmithKline Pharmaceuticals Limited has received … and documentation requirements. GlaxoSmithKline (GSK) Pharmaceuticals Limited clarified in its … appropriate action as necessary. GlaxoSmithKline Pharmaceuticals Limited, the Indian subsidiary …

GSK India plans big 'reinvention'

Mumbai: Global biopharma major GlaxoSmithKline Pharmaceuticals, best known in India for its blockbuster legacy brands Augmentin and Calpol, is charting a bold comeback in the country. The London-headquartered company, which has completed over a century in India's pharma market, is plotting its most ambitious transformation in decades as it targets doubling its India revenue to ₹8,000 crore within 4-5 years, India MD Bhushan Akshikar told ET in an exclusive interview.This will be driven by a strategic pivot from its ₹4,000-crore base of legacy portfolio of general medicines-including medications in anti-infective, pain management, respiratory and vaccines-into specialty drugs in high-growth areas of oncology and liver diseases as well as nascent areas such as adult vaccination."Reinvention and impact are the two words that define our journey in India. Taking cue from our past but remaining completely focused on the future is how I see the next decade for us," said Akshikar. "Our base business will continue to grow while on top of that we are launching in areas where we can make a sizeable impact," he added.The bet will be on innovation-led growth, accelerated clinical trials in India, and concurrent launches of global assets to double size by the end of the decade.

GSK Pharma to Procure 4.95 MWp Solar Power from CleanMax in Maharashtra

GlaxoSmithKline Pharmaceuticals (GSK Pharma ) will procure 4.95 MWp … , Syngene International, a Bengaluru-based pharmaceutical company, announced procuring renewable energy … February 2025, Mumbai-based Aarti Drugs partnered with Prozeal Green Energy …

GSK Pharma to Procure Power from CleanMax’s 4.95 MW Solar Project

GlaxoSmithKline Pharmaceuticals (GSK) has announced it will source power from a 4.95 MW solar project of Clean Max Galapagos, a special purpose vehicle (SPV) of CleanMax, in Maharashtra.

Top Diwali 2025 Picks: ICICI Bank, Varun Beverages, Finolex Among Nirmal Bang’s Favorites

Equity

From banking to beverages, Nirmal Bang’s Diwali portfolio highlights eight stocks poised for durable growth.

Mapping India’s Pharma Supply Chain Amid Shifting Global Currents

… materials, particularly active pharmaceutical ingredients (APIs) … , Executive Vice President, GlaxoSmithKline Pharmaceuticals ; Ajay Bagga, Managing … – Operations, Mankind Pharma ; Sreenivas Rao Nandigam, … Forecasting Failures in Pharma , Medical Device …

GSK re-enters India’s cancer drug market

GlaxoSmithKline Pharmaceuticals is re-entering India's oncology market with the launch of Jemperli and Zejula, precision therapies for gynaecological cancers. This move marks a strategic pivot for GSK, aiming to establish a significant oncology presence in India. The company will import these therapies, focusing on access and affordability through tiered pricing and patient assistance programs.

GlaxoSmithKline Pharmaceuticals Ltd. engages in the business of manufacturing, distributing and trading in pharmaceuticals. Its prescription medicines range across therapeutic areas such as anti-infective, dermatology, gynecology, diabetes, cardiovascular disease and respiratory diseases. The vaccines products include prevention of hepatitis A, hepatitis B, invasive disease caused by H, influenza, chickenpox, diphtheria, pertussis, tetanus, rotavirus, cervical cancer, streptococcus pneumonia and others. The company was founded in 1924 and is headquartered in Mumbai, India.

Current Price	2,532.10
Prev Close	2,540.00
Open	2,534.40
Dividend Yield	2.50%
50-Day Moving Average	2,812.30
Beta	0.04
Avg. Volume	79,038.52
PE Ratio	40.29

52-Week High	3,120.70
52-Week Low	2,088.10
Market Capitalization	429.38B
EPS (Annual)	61.15
Price to Book	18.98
Revenue Per Employee	12.32M

Feed

News

Sentiment

Fundamentals

Info

GLAXO.NSE Fundamentals